Review assesses network pharmacology for herbal medicines in rheumatoid arthritis

A review published in Molecular Biology Reports examines how network pharmacology is being used to investigate herbal medicines and bioactive compounds in rheumatoid arthritis (RA). The authors describe the approach as a systems-level strategy combining bioinformatics, multi-omics data, molecular docking and experimental validation to study interactions among compounds, molecular targets and disease pathways.

The review covers research published from January 2020 through April 2026 that was identified through searches of PubMed, Scopus, Web of Science and Google Scholar. Eligible studies investigated network pharmacology for herbal or traditional-medicine therapies for RA and reported molecular targets, pathways, phytochemicals, docking, omics analyses or experimental validation. The review was critical in summarizing the evidence; it did not generate or analyse a new dataset.

Across the studies considered, network analyses repeatedly identified pathways involving TNF, NF-κB, IL-17, Toll-like receptor signaling, PI3K/Akt, MAPK, JAK/STAT, NLRP3, oxidative stress, angiogenesis and bone-related processes. These pathways are associated in the source studies with inflammatory signaling, immune-cell regulation, synoviocyte proliferation, apoptosis, osteoclastogenesis and joint destruction in RA.

Compounds that appeared repeatedly across different herbal preparations included quercetin, kaempferol, luteolin, berberine, celastrol and triptolide. The review describes computational and experimental associations between these compounds and targets such as TNF, IL-6, PTGS2, AKT1, RELA and MAPKs. For example, studies reported effects on inflammatory pathways, macrophage or fibroblast-like synoviocyte activity, and osteoclast-related processes in cell or animal models.

The evidence was not uniform. Some investigations included molecular docking, molecular or cellular assays, metabolomics or experiments in rheumatoid arthritis models. Others relied mainly on database-based target prediction, network construction and pathway enrichment. The review notes that comparisons among studies are difficult because proposed targets, herbal materials and experimental validation methods differ substantially.

Several findings were based on preclinical models rather than human clinical outcomes. Results reported in collagen-induced arthritis or other animal models, and in cultured synoviocytes or other cell systems, cannot by themselves establish safety or effectiveness in people with RA. A small number of reviewed studies included clinical trials, but the review emphasizes limited clinical validation overall.

The authors identify several limitations in the field. They report heterogeneity among public databases, including differences in compound-target annotations and update practices, which can introduce false positives and affect network results. They also note that static target-prediction methods may not represent dynamic cellular conditions and often do not establish whether a compound acts as an agonist, antagonist or other modulator. Pharmacokinetics, botanical variation, extraction methods and formulation standardization remain additional issues.

Overall, the review concludes that network pharmacology offers a framework for target prioritization and mechanism-based investigation of multi-component herbal medicines in RA. It presents the approach as a possible bridge between traditional medicinal knowledge and systems-based drug discovery, while emphasizing that computational predictions need standardized products, experimental confirmation and controlled clinical studies before they can support therapeutic claims.

Subject of Research: Network pharmacology analysis of herbal medicines and bioactive compounds in rheumatoid arthritis

Article Title: Molecular mechanisms of herbal medicines and bioactive compounds in rheumatoid arthritis: a comprehensive network pharmacology perspective

Article References: Jasna, T. J., Sandra, K. S., Vithalkar, M. P., Vijaykumar, D., & Nayak, Y. (2026). Molecular mechanisms of herbal medicines and bioactive compounds in rheumatoid arthritis: a comprehensive network pharmacology perspective. Molecular Biology Reports, 53(1), Article 1559. https://doi.org/10.1007/s11033-026-12727-5

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12727-5

Keywords: Rheumatoid arthritis, Network pharmacology, Herbal medicine, Phytochemicals, Inflammatory signaling, Systems biology, Molecular docking, Drug discovery, Molecular, mechanisms, herbal, medicines